ICD-10 Coding for Neuroendocrine Carcinoid Tumor of Lung(C34.9, C34.90U, C34.9U)
Explore ICD-10 coding guidelines for neuroendocrine carcinoid tumors of the lung, including differentiation between malignant and benign forms.
Complete code families applicable to Neuroendocrine Carcinoid Tumor of Lung
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C7A.090 | Malignant carcinoid tumor of bronchus and lung | Use for malignant carcinoid tumors of the lung, confirmed by pathology. |
|
| C7A.1 | Malignant poorly differentiated neuroendocrine tumors | Use for poorly differentiated neuroendocrine carcinomas of the lung. |
|
| D3A.090 | Benign carcinoid tumor of bronchus and lung | Use for benign carcinoid tumors of the lung, confirmed by pathology. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutNeuroendocrine Carcinoid Tumor of Lung
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Neuroendocrine Carcinoid Tumor of Lung.
Omitting differentiation status in documentation.
Impact
Clinical: Leads to incorrect diagnosis classification., Regulatory: Non-compliance with documentation standards., Financial: Potential loss of reimbursement due to incorrect coding.
Mitigation
Include differentiation status in all pathology reports, Educate staff on documentation standards
Misclassification of neuroendocrine tumor as benign when malignant features are present.
Impact
Reimbursement: Incorrect classification can lead to reduced reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data affecting patient records.
Mitigation
Verify histologic reports for malignancy indicators such as mitotic count and necrosis.
Documentation Completeness
Impact
Incomplete documentation of tumor differentiation and mitotic count.
Mitigation
Implement standardized templates for pathology reports.